|
|
Article: ACTOS(R) (pioglitazone HCl) Shows Sustained Efficacy Throughout Two-Year Period in Patients with Type 2 Diabetes; Studies presented at American Diabetes Association annual meeting underscore long-term, multiple effects of ACTOS.
- Article from:
- PR Newswire
- Article date:
- June 5, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ORLANDO, Fla., June 5 /PRNewswire/ -- Long-term studies using the oral antidiabetic drug ACTOS(R) (pioglitazone HCl) alone, and in combination with other oral antidiabetic medications, found that it provided sustained improvements in glycemic control, insulin sensitivity and key lipid parameters over a 104-week period. The findings were presented today at the American Diabetes Association's (ADA) 64th Annual Scientific Sessions.
"Given the clinical challenges of managing diabetes patients over time, and the fact that patients are living longer with diabetes, the data being presented today on ACTOS help physicians better understand the drug's effectiveness over ...